Stemina Biomarker Discovery Prepares to Commercialize Autism Diagnostic Products; Appoints New Board Member, Heiner Dreismann, PhD, Former Head of Roche Molecular Diagnostics
Aug 25, 2017Dr. Driesmann, a leader in the diagnostics industry, will guide Stemina’s commercialization strategy. Read the full press release.
EU-ToxRisk Case Study: Developmental Toxicity Potency of Valproate Analogues in Human Pluripotent Stem Cell-Based Assay
Aug 23, 2017Presented at the 10th World Congress on Alternatives and Animal Use in the Life Sciences in Seattle, August 2017, by Stemina’s Associate Director of Toxicology, Jessica Palmer. The development and use of alternative models of safety screening in place of animal models has been at the forefront of the toxicology field for over a decade;
Utilizing devTOXqP in a Combined Testing Approach for Identifying Developmental Toxicity Liability of Chemicals [Webinar Slides]
Aug 16, 2017Why develop devTOX? Reduce prevalence of birth defects and decrease animal testing. Our approach represents a unique opportunity to screen compound safety using a human endpoint. devTOX quickPredict is a predictive, targeted biomarker assay. (devTOX Discovery, on the other hand, is a predictive, untargeted metabolomics assay.) Jessica Palmer presented this webinar in October 2016. If